Hydroxamate inhibitors of human gelatinase B (92 kDa)

Bioorganic & Medicinal Chemistry Letters
1995.0

Abstract

Gelatinase B is potently inhibited by peptide hydroxamates, including molecules that have a Rt' group which is larger than the side chains of the natural amino acids.The matrix metalloproteinases (MMPs) are a family of homologous enzymes whose substrates are molecules of the extracellular matrix) The MMPs are postulated to have a major role in normal and pathological matrix turnover, and are targets of therapeutic inhibitor design) Gelatinases A (72 kDa) and B (92 kDa) are a subgroup of the MMP family whose macromolecular substrates include proteins such as gelatin, elastin, and collagens type IV and V. The specifity of the gelatinases for peptide substrates is similar to that of the interstitial collagenases and stromelysin. 3 As secreted from cells, latent gelatinase is complexed to a molecule of TIMP: gelatinase A with TIMP-2 and gelatinase B with TIMP-1. Upon activation, the gelatinases can be inhibited by binding a second molecule of TIMP. A TIMP-free form of gelatinase B is found in the specific granules of polymorphonuclear leukocytes (PMNs), and this was the source ofgelatinase B in this study. 4The gelatinases are expressed by a number of transformed cells, and their role in tumor invasion and metastasis is an area of intense interest. 5'6 Recently, gelatinase B was shown to be expressed at high levels in human osteoclasts, which suggests a role in bone remodelling. 7In this report, we show that hydroxamate inhibitors that are known to be potent inhibitors of other MMPs are also potent inhibitors ofgelatinase B.

Knowledge Graph

Similar Paper

Hydroxamate inhibitors of human gelatinase B (92 kDa)
Bioorganic & Medicinal Chemistry Letters 1995.0
Design and synthesis of novel inhibitors of gelatinase B
Bioorganic & Medicinal Chemistry Letters 2002.0
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates
Bioorganic & Medicinal Chemistry 2007.0
Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modifications
Bioorganic & Medicinal Chemistry Letters 1995.0
Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate−Benzenesulfonamide Conjugates
Journal of Medicinal Chemistry 2008.0
Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II
European Journal of Medicinal Chemistry 2021.0
Inhibition of Matrix Metalloproteinases by Hydroxamates Containing Heteroatom-Based Modifications of the P1' Group
Journal of Medicinal Chemistry 1995.0
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions
Bioorganic & Medicinal Chemistry Letters 2009.0
Matrix metalloproteinases (MMPs): Chemical–biological functions and (Q)SARs
Bioorganic & Medicinal Chemistry 2007.0
Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors
Bioorganic & Medicinal Chemistry 2016.0